Hanmi Pharmaceutical shares surged 26% after positive Phase 3 obesity drug results, boosting R&D optimism, though analysts warn of overheating amid upcoming clinical milestones.
#YonhapInfomax #HanmiPharmaceutical #ObesityDrug #Phase3Trial #RDMomentum #SharePriceSurge #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=87561